Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 61 entries
Sorted by: Best Match Show Resources per page
[With a feeling of high responsibility].

Veterinariia

Pankin V.
PMID: 4585519
Veterinariia. 1973 Feb;49(2):24-6.

No abstract available.

Cite
Pankin V. S chuvstvom vysokoĭ otvetstvennosti. [With a feeling of high responsibility]. Veterinariia. 1973;49(2):24-6
Pankin, V. (1973). S chuvstvom vysokoĭ otvetstvennosti. [With a feeling of high responsibility]. Veterinariia, 49(2), 24-6.
Pankin, V. "S chuvstvom vysokoĭ otvetstvennosti." [With a feeling of high responsibility]. Veterinariia vol. 49,2 (1973): 24-6.
Pankin V. S chuvstvom vysokoĭ otvetstvennosti. [With a feeling of high responsibility]. Veterinariia. 1973 Feb;49(2):24-6. Russian. PMID: 4585519.
Copy Download .nbib Format: NLM
Practical Diets for Lowering Serum Lipids.

British medical journal

Pilkington TR, Stafford JL, Hankin VS, Simmonds FM, Koerselman HB.
PMID: 20788847
Br Med J. 1960 Jan 02;1(5165):23-5. doi: 10.1136/bmj.1.5165.23.

No abstract available.

Cite
Pilkington TR, Stafford JL, Hankin VS, et al. Practical Diets for Lowering Serum Lipids. Br Med J. 1960;1(5165):23-5doi: 10.1136/bmj.1.5165.23.
Pilkington, T. R., Stafford, J. L., Hankin, V. S., Simmonds, F. M., & Koerselman, H. B. (1960). Practical Diets for Lowering Serum Lipids. British medical journal, 1(5165), 23-5. https://doi.org/10.1136/bmj.1.5165.23
Pilkington, T R, et al. "Practical Diets for Lowering Serum Lipids." British medical journal vol. 1,5165 (1960): 23-5. doi: https://doi.org/10.1136/bmj.1.5165.23
Pilkington TR, Stafford JL, Hankin VS, Simmonds FM, Koerselman HB. Practical Diets for Lowering Serum Lipids. Br Med J. 1960 Jan 02;1(5165):23-5. doi: 10.1136/bmj.1.5165.23. PMID: 20788847; PMCID: PMC1966412.
Copy Download .nbib Format: NLM
Returning individual research results for genome sequences of pancreatic cancer.

Genome medicine

Johns AL, Miller DK, Simpson SH, Gill AJ, Kassahn KS, Humphris JL, Samra JS, Tucker K, Andrews L, Chang DK, Waddell N, Pajic M, Pearson JV, Grimmond SM, Biankin AV, Zeps N.
PMID: 24963353
Genome Med. 2014 May 29;6(5):42. doi: 10.1186/gm558. eCollection 2014.

BACKGROUND: Disclosure of individual results to participants in genomic research is a complex and contentious issue. There are many existing commentaries and opinion pieces on the topic, but little empirical data concerning actual cases describing how individual results have...

Cite
Johns AL, Miller DK, Simpson SH, et al. Returning individual research results for genome sequences of pancreatic cancer. Genome Med. 2014;6(5):42doi: 10.1186/gm558.
Johns, A. L., Miller, D. K., Simpson, S. H., Gill, A. J., Kassahn, K. S., Humphris, J. L., Samra, J. S., Tucker, K., Andrews, L., Chang, D. K., Waddell, N., Pajic, M., Pearson, J. V., Grimmond, S. M., Biankin, A. V., & Zeps, N. (2014). Returning individual research results for genome sequences of pancreatic cancer. Genome medicine, 6(5), 42. https://doi.org/10.1186/gm558
Johns, Amber L, et al. "Returning individual research results for genome sequences of pancreatic cancer." Genome medicine vol. 6,5 (2014): 42. doi: https://doi.org/10.1186/gm558
Johns AL, Miller DK, Simpson SH, Gill AJ, Kassahn KS, Humphris JL, Samra JS, Tucker K, Andrews L, Chang DK, Waddell N, Pajic M, Pearson JV, Grimmond SM, Biankin AV, Zeps N. Returning individual research results for genome sequences of pancreatic cancer. Genome Med. 2014 May 29;6(5):42. doi: 10.1186/gm558. eCollection 2014. PMID: 24963353; PMCID: PMC4067993.
Copy Download .nbib Format: NLM
Solvent and spectral effects in the ultrafast charge recombination dynamics of excited donor-acceptor complexes.

The journal of physical chemistry. A

Feskov SV, Ionkin VN, Ivanov AI, Hagemann H, Vauthey E.
PMID: 18181591
J Phys Chem A. 2008 Jan 31;112(4):594-601. doi: 10.1021/jp709587x. Epub 2008 Jan 09.

The charge recombination dynamics of excited donor-acceptor complexes consisting of hexamethylbenzene (HMB), pentamethylbenzene (PMB), and isodurene (IDU) as electron donors and tetracyanoethylene (TCNE) as electron acceptor in various polar solvents has been investigated within the framework of the stochastic...

Cite
Feskov SV, Ionkin VN, Ivanov AI, et al. Solvent and spectral effects in the ultrafast charge recombination dynamics of excited donor-acceptor complexes. J Phys Chem A. 2008;112(4):594-601doi: 10.1021/jp709587x.
Feskov, S. V., Ionkin, V. N., Ivanov, A. I., Hagemann, H., & Vauthey, E. (2008). Solvent and spectral effects in the ultrafast charge recombination dynamics of excited donor-acceptor complexes. The journal of physical chemistry. A, 112(4), 594-601. https://doi.org/10.1021/jp709587x
Feskov, Serguei V, et al. "Solvent and spectral effects in the ultrafast charge recombination dynamics of excited donor-acceptor complexes." The journal of physical chemistry. A vol. 112,4 (2008): 594-601. doi: https://doi.org/10.1021/jp709587x
Feskov SV, Ionkin VN, Ivanov AI, Hagemann H, Vauthey E. Solvent and spectral effects in the ultrafast charge recombination dynamics of excited donor-acceptor complexes. J Phys Chem A. 2008 Jan 31;112(4):594-601. doi: 10.1021/jp709587x. Epub 2008 Jan 09. PMID: 18181591.
Copy Download .nbib Format: NLM
Oral cancer: FAQ.

Texas dental journal

Jones DL, Rankin KV.
PMID: 23923466
Tex Dent J. 2013 May;130(5):438-43.

The efficacy of clinical examination in detecting intraoral malignances has recently been called into question, as it does not accurately predict the histological diagnosis. A brief reexamination of one study provides some insights into what this means to the...

Cite
Jones DL, Rankin KV. Oral cancer: FAQ. Tex Dent J. 2013;130(5):438-43
Jones, D. L., & Rankin, K. V. (2013). Oral cancer: FAQ. Texas dental journal, 130(5), 438-43.
Jones, Daniel L, and Rankin, K Vendrell. "Oral cancer: FAQ." Texas dental journal vol. 130,5 (2013): 438-43.
Jones DL, Rankin KV. Oral cancer: FAQ. Tex Dent J. 2013 May;130(5):438-43. PMID: 23923466.
Copy Download .nbib Format: NLM
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.

Oncotarget

Sheahan AV, Biankin AV, Parish CR, Khachigian LM.
PMID: 29765563
Oncotarget. 2018 Apr 20;9(30):21613-21627. doi: 10.18632/oncotarget.25085. eCollection 2018 Apr 20.

Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors....

Cite
Sheahan AV, Biankin AV, Parish CR, et al. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget. 2018;9(30):21613-21627doi: 10.18632/oncotarget.25085.
Sheahan, A. V., Biankin, A. V., Parish, C. R., & Khachigian, L. M. (2018). Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 9(30), 21613-21627. https://doi.org/10.18632/oncotarget.25085
Sheahan, Anjali V, et al. "Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review." Oncotarget vol. 9,30 (2018): 21613-21627. doi: https://doi.org/10.18632/oncotarget.25085
Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget. 2018 Apr 20;9(30):21613-21627. doi: 10.18632/oncotarget.25085. eCollection 2018 Apr 20. PMID: 29765563; PMCID: PMC5940404.
Copy Download .nbib Format: NLM
Solvation suppression of ion recombination in gas discharge afterglow.

Physical review. E

Amirov RK, Lankin AV, Norman GE.
PMID: 29776101
Phys Rev E. 2018 Mar;97(3):033202. doi: 10.1103/PhysRevE.97.033202.

An effect which suppresses recombination in ion plasmas is considered both theoretically and experimentally. Experimental results are presented for the ion recombination rate in fluorine plasma, which are obtained from data for the gas discharge afterglow. To interpret them,...

Cite
Amirov RK, Lankin AV, Norman GE. Solvation suppression of ion recombination in gas discharge afterglow. Phys Rev E. 2018;97(3):033202doi: 10.1103/PhysRevE.97.033202.
Amirov, R. K., Lankin, A. V., & Norman, G. E. (2018). Solvation suppression of ion recombination in gas discharge afterglow. Physical review. E, 97(3), 033202. https://doi.org/10.1103/PhysRevE.97.033202
Amirov, R Kh, et al. "Solvation suppression of ion recombination in gas discharge afterglow." Physical review. E vol. 97,3 (2018): 033202. doi: https://doi.org/10.1103/PhysRevE.97.033202
Amirov RK, Lankin AV, Norman GE. Solvation suppression of ion recombination in gas discharge afterglow. Phys Rev E. 2018 Mar;97(3):033202. doi: 10.1103/PhysRevE.97.033202. PMID: 29776101.
Copy Download .nbib Format: NLM
High-resolution large-scale plasmonic laser color printing for jewelry applications.

Optics express

Odintsova GV, Vlasova EA, Andreeva YM, Moskvin MK, Krivonosov AS, Gorbunova EV, Pankin DV, Medvedev OS, Sergeev MM, Shchedrina NN, Lutoshina DS, Veiko VP.
PMID: 30732383
Opt Express. 2019 Feb 04;27(3):3672-3681. doi: 10.1364/OE.27.003672.

We offer to use optical features of surface plasmon resonance in Ag nanoparticles for jewelry application as a method for the well-controlled decoration of silver items. The novel approach of silver nanoparticles formation with sizes from 5 to 50...

Cite
Odintsova GV, Vlasova EA, Andreeva YM, et al. High-resolution large-scale plasmonic laser color printing for jewelry applications. Opt Express. 2019;27(3):3672-3681doi: 10.1364/OE.27.003672.
Odintsova, G. V., Vlasova, E. A., Andreeva, Y. M., Moskvin, M. K., Krivonosov, A. S., Gorbunova, E. V., Pankin, D. V., Medvedev, O. S., Sergeev, M. M., Shchedrina, N. N., Lutoshina, D. S., & Veiko, V. P. (2019). High-resolution large-scale plasmonic laser color printing for jewelry applications. Optics express, 27(3), 3672-3681. https://doi.org/10.1364/OE.27.003672
Odintsova, G V, et al. "High-resolution large-scale plasmonic laser color printing for jewelry applications." Optics express vol. 27,3 (2019): 3672-3681. doi: https://doi.org/10.1364/OE.27.003672
Odintsova GV, Vlasova EA, Andreeva YM, Moskvin MK, Krivonosov AS, Gorbunova EV, Pankin DV, Medvedev OS, Sergeev MM, Shchedrina NN, Lutoshina DS, Veiko VP. High-resolution large-scale plasmonic laser color printing for jewelry applications. Opt Express. 2019 Feb 04;27(3):3672-3681. doi: 10.1364/OE.27.003672. PMID: 30732383.
Copy Download .nbib Format: NLM
ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Oncogenesis

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.
PMID: 30442938
Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma that harbors tumor-promoting properties. No good biomarkers exist to monitor the effect of stromal targeting therapies or to predict response. We set out to identify such non-invasive markers for PDAC...

Cite
Veenstra VL, Damhofer H, Waasdorp C, et al. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018;7(11):87doi: 10.1038/s41389-018-0096-9.
Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K., Bailey, P. J., Biankin, A. V., Kocher, H. M., Medema, J. P., Li, J. S., Jiang, R., Pierce, D. W., van Laarhoven, H. W. M., & Bijlsma, M. F. (2018). ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7(11), 87. https://doi.org/10.1038/s41389-018-0096-9
Veenstra, V L, et al. "ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy." Oncogenesis vol. 7,11 (2018): 87. doi: https://doi.org/10.1038/s41389-018-0096-9
Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9. PMID: 30442938; PMCID: PMC6237826.
Copy Download .nbib Format: NLM
Mitochondrial mutations and metabolic adaptation in pancreatic cancer.

Cancer & metabolism

Hardie RA, van Dam E, Cowley M, Han TL, Balaban S, Pajic M, Pinese M, Iconomou M, Shearer RF, McKenna J, Miller D, Waddell N, Pearson JV, Grimmond SM, Sazanov L, Biankin AV, Villas-Boas S, Hoy AJ, Turner N, Saunders DN.
PMID: 28163917
Cancer Metab. 2017 Jan 30;5:2. doi: 10.1186/s40170-017-0164-1. eCollection 2017.

BACKGROUND: Pancreatic cancer has a five-year survival rate of ~8%, with characteristic molecular heterogeneity and restricted treatment options. Targeting metabolism has emerged as a potentially effective therapeutic strategy for cancers such as pancreatic cancer, which are driven by genetic...

Cite
Hardie RA, van Dam E, Cowley M, et al. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab. 2017;5:2doi: 10.1186/s40170-017-0164-1.
Hardie, R. A., van Dam, E., Cowley, M., Han, T. L., Balaban, S., Pajic, M., Pinese, M., Iconomou, M., Shearer, R. F., McKenna, J., Miller, D., Waddell, N., Pearson, J. V., Grimmond, S. M., Sazanov, L., Biankin, A. V., Villas-Boas, S., Hoy, A. J., Turner, N., & Saunders, D. N. (2017). Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer & metabolism, 52. https://doi.org/10.1186/s40170-017-0164-1
Hardie, Rae-Anne, et al. "Mitochondrial mutations and metabolic adaptation in pancreatic cancer." Cancer & metabolism vol. 5 (2017): 2. doi: https://doi.org/10.1186/s40170-017-0164-1
Hardie RA, van Dam E, Cowley M, Han TL, Balaban S, Pajic M, Pinese M, Iconomou M, Shearer RF, McKenna J, Miller D, Waddell N, Pearson JV, Grimmond SM, Sazanov L, Biankin AV, Villas-Boas S, Hoy AJ, Turner N, Saunders DN. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab. 2017 Jan 30;5:2. doi: 10.1186/s40170-017-0164-1. eCollection 2017. PMID: 28163917; PMCID: PMC5282905.
Copy Download .nbib Format: NLM
Clinical and molecular characterization of HER2 amplified-pancreatic cancer.

Genome medicine

Chou A, Waddell N, Cowley MJ, Gill AJ, Chang DK, Patch AM, Nones K, Wu J, Pinese M, Johns AL, Miller DK, Kassahn KS, Nagrial AM, Wasan H, Goldstein D, Toon CW, Chin V, Chantrill L, Humphris J, Mead RS, Rooman I, Samra JS, Pajic M, Musgrove EA, Pearson JV, Morey AL, Grimmond SM, Biankin AV.
PMID: 24004612
Genome Med. 2013 Aug 31;5(8):78. doi: 10.1186/gm482. eCollection 2013.

BACKGROUND: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer,...

Cite
Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013;5(8):78doi: 10.1186/gm482.
Chou, A., Waddell, N., Cowley, M. J., Gill, A. J., Chang, D. K., Patch, A. M., Nones, K., Wu, J., Pinese, M., Johns, A. L., Miller, D. K., Kassahn, K. S., Nagrial, A. M., Wasan, H., Goldstein, D., Toon, C. W., Chin, V., Chantrill, L., Humphris, J., Mead, R. S., Rooman, I., Samra, J. S., Pajic, M., Musgrove, E. A., Pearson, J. V., Morey, A. L., Grimmond, S. M., & Biankin, A. V. (2013). Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome medicine, 5(8), 78. https://doi.org/10.1186/gm482
Chou, Angela, et al. "Clinical and molecular characterization of HER2 amplified-pancreatic cancer." Genome medicine vol. 5,8 (2013): 78. doi: https://doi.org/10.1186/gm482
Chou A, Waddell N, Cowley MJ, Gill AJ, Chang DK, Patch AM, Nones K, Wu J, Pinese M, Johns AL, Miller DK, Kassahn KS, Nagrial AM, Wasan H, Goldstein D, Toon CW, Chin V, Chantrill L, Humphris J, Mead RS, Rooman I, Samra JS, Pajic M, Musgrove EA, Pearson JV, Morey AL, Grimmond SM, Biankin AV. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013 Aug 31;5(8):78. doi: 10.1186/gm482. eCollection 2013. PMID: 24004612; PMCID: PMC3978667.
Copy Download .nbib Format: NLM
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.

Seminars in cancer biology

Normanno N, Apostolides K, de Lorenzo F, Beer PA, Henderson R, Sullivan R, Biankin AV, Horgan D, Lawler M.
PMID: 34389490
Semin Cancer Biol. 2021 Aug 10; doi: 10.1016/j.semcancer.2021.08.002. Epub 2021 Aug 10.

Cancer Biomarkers are the key to unlocking the promise of precision oncology, selecting which patients will respond to a more personalised treatment while sparing non-responders the therapy-related toxicity. In this paper, we highlight the primacy of cancer biomarkers, but...

Cite
Normanno N, Apostolides K, de Lorenzo F, et al. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Semin Cancer Biol. 2021;doi: 10.1016/j.semcancer.2021.08.002.
Normanno, N., Apostolides, K., de Lorenzo, F., Beer, P. A., Henderson, R., Sullivan, R., Biankin, A. V., Horgan, D., & Lawler, M. (2021). Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Seminars in cancer biology, . https://doi.org/10.1016/j.semcancer.2021.08.002
Normanno, Nicola, et al. "Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems." Seminars in cancer biology vol. (2021). doi: https://doi.org/10.1016/j.semcancer.2021.08.002
Normanno N, Apostolides K, de Lorenzo F, Beer PA, Henderson R, Sullivan R, Biankin AV, Horgan D, Lawler M. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Semin Cancer Biol. 2021 Aug 10; doi: 10.1016/j.semcancer.2021.08.002. Epub 2021 Aug 10. PMID: 34389490.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 61 entries